Volume 7, Issue 8 , Pages 868-873.e2, August 2009
Clostridium difficile Strain NAP-1 Is Not Associated With Severe Disease in a Nonepidemic Setting
Background & Aims
Recent outbreaks of Clostridium difficile infection (CDI) in North America and in Europe with very high case-fatality rates have been associated with infection by North American Pulsed Field Type I (NAP-1) isolates. This study examined whether NAP-1 strains are associated with worse outcomes of CDI in a nonepidemic, nosocomial setting.
Methods
All cases of CDI that occurred over a 13-month period at a tertiary medical center were examined for risk factors associated with increased severity of CDI and other outcomes. Stool samples from each patient were cultured for C difficile and the resulting isolates were strain-typed by pulsed-field gel electrophoresis.
Results
Strain types were obtained from 236 of 272 CDI samples; the NAP-1 strain was identified in 59 (25%). In this inpatient cohort of patients with CDI, the incidence of in hospital death was 12.1% and of death caused by CDI was 4.0%. Of the patients with CDI, 22.1% met the combined outcome end point of severe CDI. In both univariate and multivariate analyses, patients infected with the NAP-1 strain did not have worse outcomes compared with those infected with non-NAP-1 strains. Infection with the NAP-1 strain was correlated with admission from outside health care facilities regardless of whether symptoms of CDI began before or after admission to the study hospital.
Conclusions
The NAP-1 strain of C difficile was found to cause 25% of cases of CDI in the hospital where the study was performed. However, compared with non-NAP-1 strains, CDI was not associated with increased severity of disease in this nonepidemic setting.
Abbreviations used in this paper: BIDMC, Beth Israel Deaconess Medical Center, CDI, Clostridium difficile infection, CI, confidence interval, ICU, intensive care unit, NAP-1, North American Pulsed Field Type I, PCR, polymerase chain reaction, PFGE, pulsed field gel electrophoresis
Conflicts of interest The authors disclose the following: Ciarán P. Kelly has acted as a scientific consultant for Acambis, Actelion, BioHelix, Genzyme, Merck, Replidyne, Salix, and ViroPharm, or has received research grant funding from Actelion, and Genzyme companies that were working toward developing new diagnostic tests or treatments for CDI. He has also served as an expert witness in medical legal cases related to CDI. The remaining authors disclose no conflicts.
Funding This work was supported by grants from the National Institutes of Health (RO-1 AI053069 to Ciarán P. Kelly; K30-HL04095 for the Scholars in Clinical Science Program at Harvard Medical School, in which Mary Y. Hu was enrolled. Jeffrey Cloud received grant support from Massachusetts Biologics Laboratories.
PII: S1542-3565(09)00445-5
doi:10.1016/j.cgh.2009.05.018
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.
Volume 7, Issue 8 , Pages 868-873.e2, August 2009


